Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 30 June 2017 | By Zachary Brennan
The US Centers for Medicare and Medicaid Services (CMS) on Friday released 2016 data on more than $8 billion in payments (which is on par with 2015 data) made by 1,481 pharmaceutical, biotech and medical device companies to more than 600,000 physicians and 1,146 hospitals.
In total, CMS calculated that $2.8 billion was spent on general payments and $4.36 billion on research payments.
In its breakdown of the numbers, CMS says that more than $1 billion in 2016 was spent on physicians for speaking, training and education engagements that are not for continuing education, and on royalties or other payments based on sales of products that use a physician’s intellectual property.
And more than $430 million in 2016 was spent on food, beverages, travel and lodging, which compares to about $440 million in 2015.
The database also breaks down the figures by company, though some of the multinational biopharmaceutical companies, like Roche and Johnson & Johnson, did not disclose complete numbers that matched their peers for 2016. The following is a breakdown of what was listed for some of the largest companies (in alphabetical order):
Tags: CMS open payments, drug industry payments to doctors